CCR2 and neoplasm: Additionally, I utilized CCR2 knockout mice to demonstrate the dependence of progression of TC1 tumor on CCR2 signaling.I also used a thioglycolate-induced peritonitis model of inflammation to validate the ability of a CCR2 antagonist to inhibit trafficking of MDSCs to the site of inflammation and then tested the compound at this inhibitory concentration for its ability to impair CCR2 chemokine signaling within established tumors.